Core Viewpoint - Aptevo Therapeutics Inc. (APVO) has shown a downtrend recently, losing 12% over the past week, but a hammer chart pattern suggests a potential trend reversal as buying interest may be emerging [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottoming out, with selling pressure likely subsiding, which could lead to a bullish trend for the stock [2][5]. - A hammer pattern forms when there is a small candle body with a long lower wick, signaling that bears may be losing control over the price [4][5]. - The occurrence of this pattern at the bottom of a downtrend suggests that bulls have successfully halted further price declines, indicating a potential trend reversal [5]. Fundamental Analysis - There has been a notable upward trend in earnings estimate revisions for APVO, which is a bullish indicator suggesting potential price appreciation [7]. - The consensus EPS estimate for the current year has increased by 62.1% over the last 30 days, reflecting strong agreement among analysts regarding the company's improved earnings potential [8]. - APVO holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10].

Core Insights - Aptevo Therapeutics has presented preclinical data for its trispecific antibody candidate, APVO451, at the Society for Immunotherapy of Cancer Annual Meeting, highlighting its potential in treating hard-to-treat solid tumors [1][2]. Company Update - APVO451 is designed to address the challenge of immune suppression in solid tumors, such as urothelial, breast, and pancreatic cancers, by utilizing a proprietary CRIS-7-derived CD3 binding domain [2][3]. - The molecule aims to activate the intratumoral immune system, enhancing the ability to target and kill tumor cells effectively [3]. Key Findings from the Presentation - APVO451 demonstrated local activation of T-cells and antigen-presenting cells (APCs) only when bound to the target protein, nectin-4, indicating a favorable safety profile [4]. - The candidate showed dual immune re-activation by stimulating T-cell effector functions and restoring APC function, addressing a common failure point in solid tumor treatments [4]. - In tumor models simulating suppression, APVO451 was more effective in eliminating nectin-4-positive tumor cells compared to standard CD3 T-cell engagers, suggesting its potential to overcome suppressive tumor environments [4]. Next Steps - Aptevo is advancing APVO451 through ongoing preclinical studies to support IND-enabling work and future clinical development targeting nectin-4-expressing solid tumors [5]. About APVO451 - APVO451 is a trispecific ADAPTIR-FLEX therapeutic candidate designed to engage CD3 and CD40, aiming to restore immune engagement in suppressive solid tumors while minimizing off-tumor activation [6]. About Aptevo Therapeutics - Aptevo Therapeutics is a clinical-stage biotechnology company focused on developing novel bispecific and trispecific immunotherapies for cancer treatment, with two clinical candidates currently in trials [7].

Clinical Development - Mipletamig reported an 89% remission rate among evaluable frontline AML patients, with 100% remission in Cohort 3 of the ongoing RAINIER trial[99]. - No cytokine release syndrome (CRS) observed among evaluable frontline patients to date, distinguishing it from other treatments[99]. - The ongoing Phase 1b trial for mipletamig was initiated in August 2024, with favorable results reported to date[91]. - The company has two clinical candidates and six preclinical candidates currently in development, focusing on novel immunotherapy for cancer treatment[91]. - The company has an obligation to make a $2.0 million milestone payment upon dosing the first patient in a Phase 2 clinical trial of mipletamig under the OMT License Agreement[124]. Financial Performance - Research and development expenses increased by $0.9 million to $4.0 million for the three months ended September 30, 2025, compared to $3.1 million for the same period in 2024[102]. - General and administrative expenses rose by $1.5 million to $3.6 million for the three months ended September 30, 2025, compared to $2.1 million for the same period in 2024[104]. - Net cash provided by financing activities was $32.7 million for the nine months ended September 30, 2025, compared to $8.9 million for the same period in 2024[109]. - Total research and development expenses for the nine months ended September 30, 2025, were $11.0 million, up from $10.5 million in the same period in 2024[102]. - For the nine months ended September 30, 2025, net cash used in operating activities was $20.4 million, indicating ongoing operational losses[117]. - The company anticipates significant operating losses for the next several years as it continues to develop its product candidates, requiring substantial additional funding[117]. Capital Raising and Agreements - The company raised $18.7 million net in the third quarter, extending cash runway into Q4 2026[99]. - The company entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville, allowing the issuance of up to $25 million in common stock over 36 months, with $15 million raised from 8.3 million shares issued as of September 30, 2025[110]. - Under the At The Market Offering Agreement (ATM Agreement), the company raised $7.6 million from the issuance of 2.8 million shares at an average price of $2.74 per share for the nine months ended September 30, 2025[111]. - The company has no remaining availability under the ATM Agreement due to limitations, but has $10 million remaining under the SEPA[111][118]. - The company has 12,535,033 common warrants outstanding, which could yield up to $23.9 million in gross proceeds if exercised[115]. - The company received $9.6 million from XOMA for the sale of future deferred payments and potential milestones related to IXINITY, with an additional $5.8 million in milestone payments contingent on regulatory achievements[114]. Market and Operational Challenges - The company may face delays in clinical trials and partnerships due to macroeconomic factors, including inflation and potential impacts on partners' financial stability[120]. - The company has cash and cash equivalents of $21.1 million and an accumulated deficit of $269.2 million as of September 30, 2025[116].

Clinical Trials and Product Development - 89% of evaluable frontline AML patients achieved remission with mipletamig in combination therapy across two trials, including 100% remission in Cohort 3 of the RAINIER trial[3] - Aptevo introduced its first trispecific T-cell engagers, APVO451 and APVO452, expanding its oncology portfolio to five CRIS-7-derived CD3-targeting molecules[4] - Aptevo's pipeline now includes six preclinical candidates targeting various solid tumors, leveraging its proprietary ADAPTIR and ADAPTIR-FLEX platforms[18] Financial Performance - The company raised $18.7 million in Q3 2025 and an additional $4.1 million post-quarter, extending its cash runway into Q4 2026[10] - Cash and cash equivalents totaled $21.1 million as of September 30, 2025, increasing to $25.2 million after additional fundraising[10] - Research and development expenses rose to $4.0 million in Q3 2025, up from $3.1 million in Q3 2024, primarily due to increased mipletamig and employee costs[11] - General and administrative expenses increased to $3.6 million in Q3 2025, compared to $2.1 million in Q3 2024, mainly due to higher employee costs[12] - Aptevo reported a net loss of $7.5 million or $2.23 per share for Q3 2025, compared to a net loss of $5.1 million or $357.86 per share in Q3 2024[12] - The total assets of Aptevo increased to $26.996 million as of September 30, 2025, from $15.591 million at the end of 2024[15] - The company’s accumulated deficit reached $269.2 million as of September 30, 2025, compared to $247.6 million at the end of 2024[15] Risks and Uncertainties - Aptevo's actual results may differ materially from forward-looking statements due to various risks, including clinical trial uncertainties and regulatory changes[21] - The company faces known and unknown risks that could impact the availability or commercial potential of its product candidates[21] - Macroeconomic conditions such as rising inflation, interest rates, and decreased consumer confidence are potential factors affecting Aptevo's performance[21] - The ongoing geopolitical risks, including the war between Russia and Ukraine, may also influence the company's business environment[21] - Aptevo does not assume any obligation to update forward-looking statements unless required by law[21]

Core Points - The article emphasizes the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1] Summary by Categories Technical Requirements - Users are advised to enable Javascript and cookies in their browsers to ensure proper functionality [1] - The presence of ad-blockers can lead to blocked access, necessitating their temporary disablement [1]

Core Insights - Aptevo Therapeutics reported that 89% of evaluable frontline AML patients achieved remission in combination therapy across two trials, with a notable 100% remission rate in Cohort 3 of the ongoing RAINIER trial [1][1][1] - The company introduced its first trispecific molecules, APVO451 and APVO452, aimed at overcoming immune suppression in certain solid tumors, utilizing a unique CRIS-7-derived CD3 binding domain [1][1][1] - Aptevo's CD3 T-cell engager portfolio has been expanded to five molecules, indicating growth in its therapeutic offerings [1][1][1] - The company raised $18.7 million in the third quarter and an additional $4.1 million since the quarter ended, extending its cash runway into the fourth quarter of 2026 [1][1][1] Financial Performance - The financial results for the quarter ended September 30, 2025, were reported alongside a business update, highlighting the company's ongoing development in immune-oncology therapeutics [1][1][1]

Core Insights - Aptevo Therapeutics is actively participating in several key financial, industry, scientific, and medical conferences this fall to showcase its ongoing developments and momentum in the biotechnology sector [1] Conference Participation - Aptevo will participate in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, discussing its lead asset mipletamig and its clinical progress in Acute Myeloid Leukemia (AML) [1] - The company will also be present at the Biotechnology Innovation Organization (BIO)-Europe 2025 from November 3-5, 2025, engaging in meetings at the largest biotechnology event in Europe [1] - At the Society of Immunotherapy in Cancer (SITC) 2025, scheduled for November 5-9, 2025, Aptevo's R&D team will present a poster on a novel trispecific targeting approach to address the immunosuppressive tumor microenvironment [1] - The interim results from the ongoing Phase 1b/2 RAINIER trial evaluating mipletamig in frontline combination therapy for AML will be presented at the American Society of Hematology (ASH) 2025 meeting from December 6-9, 2025 [1]

Group 1: Telomir Pharmaceuticals Inc - Telomir Pharmaceuticals Inc's shares rose 31% to $1.86 in pre-market trading following the release of promising preclinical study results for its lead compound, Telomir-1 [1] - The preclinical study indicated that Telomir-1 was able to reverse abnormal DNA methylation in aggressive prostate cancer models [1] Group 2: Other Stocks in Pre-Market Trading - Spruce Biosciences Inc gained 90.9% to $248.89, while C3is Inc surged 73.3% to $3.83 in pre-market trading [5] - Aptevo Therapeutics Inc increased by 40.2% to $1.98, and Galecto Inc rose 37.5% to $5.10 [5] - Datavault AI Inc surged 27.8% to $2.66, reaffirming its 2H 2025 revenue guidance of $12 million to $15 million [5] - Processa Pharmaceuticals Inc gained 27.5% to $0.36, and BTQ Technologies Corp rose 25.7% to $11.44 [5] - DBV Technologies SA gained 12.8% to $14.99 after announcing the sale of approximately $30 million of ADSs [5] - Amkor Technology Inc jumped 11.2% to $33.99, announcing an expanded investment in semiconductor packaging and testing in Arizona [5] Group 3: Declining Stocks - Society Pass Inc shares dipped 24.6% to $4.00 after a significant jump of 276% on Monday [5] - Dermata Therapeutics Inc fell 19.1% to $4.35, and Aether Holdings Inc declined 16.8% to $4.51 [5] - SANUWAVE Health Inc dipped 14.4% to $34.99, cutting its FY25 revenue guidance from $48 million-$50 million to $44 million-$46 million [5] - Lazydays Holdings Inc fell 12.3% to $2.57, while NOVONIX Ltd tumbled 12.3% to $1.57 [5] - OneMedNet Corp dipped 12.1% to $2.25 after a significant jump of 149% on Monday [5]

As filed with the Securities and Exchange Commission on October 1, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 APTEVO THERAPEUTICS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 81-1567056 (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 2401 4th Avenue, ...

Market Overview - U.S. stocks experienced an upward trend, with the Dow Jones index increasing by over 150 points, closing up 0.37% at 46,190.85, NASDAQ rising 1.07% to 22,500.28, and S&P 500 gaining 0.62% to 6,641.29 [1] - In the commodities market, oil prices rose by 0.7% to $64.50, while gold decreased by 1.2% to $3,674.30 [5] Company Performance - Darden Restaurants, Inc. reported first-quarter earnings of $1.97 per share, missing the analyst consensus estimate of $2.00 per share, and quarterly sales of $3.004 billion, which also fell short of the $3.040 billion estimate [2] - 89bio, Inc. shares surged 86% to $15.02 following an acquisition agreement with Roche [8] - Intel Corporation's shares increased by 27% to $31.59 after announcing a partnership with NVIDIA for AI infrastructure development, with NVIDIA investing $5 billion in Intel's stock at $23.28 per share [8] - Aptevo Therapeutics Inc. saw its shares rise by 62% to $2.2863 due to breakthrough clinical results for its drug in AML treatment [8] - Replimune Group, Inc. shares fell by 39% to $3.4900 as the company assesses FDA feedback on its product [8] - BioCardia, Inc. shares dropped 29% to $1.0850 after announcing a public offering and trial results [8] - Lifeway Foods, Inc. shares decreased by 21% to $26.72 following Danone's withdrawal of its acquisition proposal [8] Economic Indicators - U.S. initial jobless claims decreased by 33,000 to 231,000, better than the market estimate of 240,000 [10] - The Philadelphia Fed Manufacturing Index rose to +23.2 in September, the highest since January, compared to -0.3 in August [10] European and Asian Markets - European shares showed positive movement, with the eurozone's STOXX 600 rising by 0.79% and major indices in Spain, London, Germany, and France also gaining [6] - Asian markets closed mixed, with Japan's Nikkei gaining 1.15% while Hong Kong's Hang Seng fell by 1.35% [7]